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Electrospun organic–inorganic nanohybrids as
sustained release drug delivery systems†
Yanshan Gao,ab Tian Wei Teoh,b Qiang Wang *a and Gareth R. Williams *b
In this work, the non-steroidal anti-inflammatory drugs ibuprofen (ibu) and ketoprofen (ket), both poorly
soluble in water, were first intercalated into layered double hydroxide (LDH) nanoparticles. The drug–
LDH composites were then mixed with poly(e-caprolactone) (PCL) at 5% and 10% w/w ratios and
processed into fibers via electrospinning, yielding organic–inorganic nanohybrids. PCL/drug fibers
were additionally prepared as controls. The average diameter of the fibers ranged from 400 to 1000 nm.
The fibers are found to be smooth and cylindrical, with the LDH-containing systems having more
homogenous fibers than those without the inorganic filler. From in vitro drug release tests, it
was determined that more than 90% of the intercalated ibu and ket were released from the drug–LDH
nanohybrids within the first 4 hours. Similarly, more than 60% of the incorporated drug was freed from the
PCL/drug fibers in this time period. However, the release rates of both ibu and ket from the drug–LDH
loaded PCL fibers were significantly slower. Only 44–48% of ibu was released from the PCL/ibu–LDH
system after 5 days, while the amount released in the case of ket was 20–25%. In addition, drug release
was still ongoing after 5 days for all the PCL/drug–LDH samples. These systems are thus proposed to have
potential as implantable drug delivery systems.
1. Introduction
Biodegradable and biocompatible polymers have been widely
explored in drug delivery.1 Amongst these, poly(e-caprolactone)
(PCL) has received significant attention because of its slow degra-
dation rate (E3 years in vivo), which lends it to the preparation of
long-lasting implants. PCL has been processed using a wide variety
of pharmaceutical technologies, including with the electro-
spinning approach. The latter comprises a facile and scalable
method to generate fibers from polymer solutions or melts.2,3
In solution electrospinning, a polymer and functional com-
ponent (such as a drug) are first dissolved in a volatile solvent.
The resultant solution is ejected from a syringe fitted with a
metal tip towards a metal collector plate, with a high potential
diﬀerence applied between the two. The electrical energy causes
the solvent to evaporate rapidly, resulting in one-dimensional
fibers in which the drug is typically dispersed as a solid solution
in the polymer. Usually the fiber diameter ranges from a few
nanometers to a few micrometers.4–6 Electrospun drug loaded
fibers have been widely explored for targeted release, for improving
the dissolution rate of poorly water-soluble drugs, and for
encapsulating multiple functional components.7–10
However, when fabricating nanofibers a burst release of
drug is often observed even if the polymer filament is insoluble
in water (as is the case for PCL). This arises because of the very
high surface area-to-volume ratio of the fibers, which results in
a large proportion of the incorporated drug molecules being
present at or near the fiber surfaces. These molecules can
rapidly diﬀuse into the release medium, leading to an initial burst
release. A number of authors have explored this phenomenon,4,11,12
and the principal strategy used to ameliorate burst release has
been to prepare core/shell fibers with drug present in the core
component only. In such systems, the drug molecules must
diﬀuse through the blank polymer shell before exiting the fibers,
and thus the burst eﬀect can often be prevented.13–16 However,
the production of core/shell fibers is not a panacea, and several
studies have shown that simply having a blank polymer shell
surrounding a drug-loaded core does not always prevent the
initial burst of release.17,18 A potentially more powerful route to
preclude burst release is using triaxial electrospinning to generate
three-layer fibers with a gradient distribution of drug.19
An alternative approach is to prepare fibers loaded with drug-
containing nanoparticles. Some studies have been performed
exploring this option, and it has been shown to have potential.
For instance, when fibers of poly(lactic-co-glycolic acid) containing
rhodamine B-loaded mesoporous silica nanoparticles were
prepared, rhodamine release was slowed compared to the silica
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nanoparticles alone.20 Wang et al.21 studied composite PCL
fibers containing chitosan nanoparticles loaded with naproxen
or rhodamine B, and found the properties of the drug to have a
major influence on the release rate. In other work, Polacco and
co-workers prepared fibers of poly(lactic acid)/e-caprolactone
copolymers containing poly(DL-lactide-co-glycolide) and gelatin
nanoparticles loaded with various drugs.22 It was postulated that
these fibers could have applications in targeted delivery. Despite
its evident promise, however, the production of nanoparticle-
loaded fibers has been less explored than the core/shell fiber
technique. In this work we sought to explore the use of layered
double hydroxide (LDH) nanoparticles as drug carriers.
LDHs, also commonly called anionic clays, are a class of
lamellar compounds made up of positively charged mixed-
metal hydroxide layers with an interlayer region containing
charge compensating anions and water molecules (Fig. 1(a)).




q+(Xn)q/nyH2O, whereMz+ is typically a divalent
cation (such as Mg2+, Zn2+, or Ca2+), M3+ is Fe3+ or Al3+, and X is a
charge balancing interlayer anion (which can range from simple
ions such as Cl, NO3
 or CO3
2 to complex biomolecules).
Electrostatic interactions and hydrogen bonds between the layers
and the contents of the interlayer space hold adjacent layers
together, forming a three-dimensional structure.23,24 The earliest
application of LDHs in relation to human health was their use as
antacids and antipeptic reagents in 1996,25 and in the last
decade nanometer-sized LDH materials (50–300 nm) have been
increasingly explored as drug and gene carriers and delivery
systems.26 Many drugs (e.g. the non-steroidal anti-inflammatory
drugs ibuprofen (ibu) and ketoprofen (ket); Fig. 1(b)) are weak
acids, and thus can be deprotonated to form anions and then
incorporated between the layers of an LDH system. This can
lead to drug release profiles different to traditional commercial
formulations.12,27
Advantages often cited for LDHs in drug delivery are that they
provide protection (e.g. to UV light or heat-mediated degradation)
of the incorporated anions, can improve the solubility of poorly
water-soluble drugs, and can reduce side eﬀects.28 However, like
electrospun fibers LDH–drug intercalates commonly suffer
from an initial burst release which cannot be controlled. In
this work, we sought to incorporate drug-loaded LDH particles
into PCL fibers to determine whether the production of
such organic–inorganic nanohybrids can resolve this issue.
A schematic diagram illustrating our approach is depicted in
Fig. 1(c). Ibuprofen and ketoprofen were used as model drugs
with poor solubility, and because sustained release formula-
tions of these active ingredients could be of major benefit for
the treatment of diseases such as arthritis.
To date, there are a few reports of polymer/LDH composites
prepared by electrospinning in the literature, but in general
such studies are focused on the preparation of advanced
electronics materials or absorbents, or use the LDH to improve
the mechanical properties of the fibers. For instance, Birajdar
et al.29 have used poly(vinylidene fluoride)/LDH fibers to
remove Cu(II) ions from wastewater, and Qin and co-workers30
report that adding LDHs to poly(vinyl alcohol) fibers causes the
tensile strength and elongation at break to increase. Romeo
and co-workers31 generated PCL/LDH fibers using the Mg/Al
LDH and found that when the interlayer anion was carbonate
the LDH particles were deposited at the outside of the fibers, but
when the guest was 12-hydroxydodecanoate the LDH particles
were largely exfoliated and evenly dispersed throughout the
polymer matrix. This is expected to be because the surfactant
molecules surround the hydrophilic LDH layers and reduce the
interfacial tension between these and the hydrophobic PCL.
The size of the LDH particles has also been shown to aﬀect
the properties of LDH-loaded electrospun fibers.32
In the biomedical setting, Shafiei et al.33 fabricated PCL
composites with diﬀerent LDH loadings by electrospinning and
determined that the blend fibers had improved mechanical
properties over pure PCL fibers, with higher tensile strength
and elongation at break values. In addition, the adhesion,
proliferation, and diﬀerentiation of multipotent mesenchymal
stem cells were significantly improved by the addition of the
LDH. There are also a few studies employing polymer/LDH
fibers for drug delivery. The first report came from Tammaro
and co-workers,2 who encapsulated LDH particles intercalated
with diclofenac into PCL by electrospinning. PCL/diclofenac
fibers exhibited an extreme burst of release, while the compo-
site PCL/LDH-diclofenac fibers could eﬀectively retard release
and mitigate the burst.
However, this is not universally observed. Miao et al.11 pro-
duced ibuprofen drug-delivery systems from PCL and poly(lactic
acid) using both the neat drug and Mg/Al LDH intercalated with
ibuprofen. The use of the LDH here did not have any significant
eﬀect on the amount of burst release observed: in most cases,
the release profiles leveled oﬀ very quickly (within ca. 1 h of the
start of the release experiment), and although the presence of
LDH does aﬀect the maximum percentage release reached it
does not change the overall shape of the release profiles. In
other work, amoxicillin-intercalated LDH has been loaded into
PCL fibers; a burst of release approaching 50% of the loading
occurred during the first day of the release experiment.34 The
most recent report in this area comes from Yang et al. and is
Fig. 1 A schematic diagram showing (a) the general structure of an LDH,
(b) the chemical structures of ibuprofen and ketoprofen, and (c) the
strategy adopted in this work.
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concerned with fibers based on poly(lactic-co-glycolic acid) and
loaded with an Mg/Al LDH intercalated with flurbiprofen
axetil.35 The presence of the LDH in the fibers could reduce
the initial burst of release, and slowed down the rate at which
the drug was freed into solution.
Where the polymer used for fiber formation is hydrophilic,
the polar nature of the LDH particle surface should result in
good compatibility between the two phases and the formation
of a homogeneously-mixed composite with long term stability.
In contrast, with a hydrophobic polymer such as PCL the two
phases will have a tendency to separate, as noted by Romeo.31
Organic modification of the LDH surface using amphiphilic
molecules such as surfactants can be used to ameliorate this
problem. One route to achieve this is the aqueous miscible
organic solvent treatment (AMOST), which results in stable,
transparent dispersions of hydrophilic LDHs in nonpolar
solvents.36,37 This simple technique uses organic solvents to
wash LDH particles immediately after synthesis and can tune
the surface of LDHs to be hydrophobic, enabling them to
be eﬀectively dispersed in apolar environments.38–40 AMOST
modified LDHs have also been found to disperse better in
hydrophobic polymers than unmodified LDH particles.
In this study, aqueous miscible organic layered double
hydroxides (AMO-LDHs) were used to prepare PCL/LDH
systems, with the aim of producing a homogeneous LDH
dispersion in the polymer. We employed an LDH based
on Mg and Al ([Mg2Al(OH)6]XyH2O, where X represents the
interlayer anion) because of the biocompatibility of these
metals. First, the model drugs ibuprofen and ketoprofen were
intercalated into the MgAl–LDH interlayer, and the products fully
characterized. Next, the LDH nanoparticles were encapsulated
into a PCL matrix via electrospinning. Following an in-depth
characterization of the fibers, a systematic study exploring drug




Materials were procured as follows: poly(e-caprolactone) (PCL;
Mn = 70 000–90 000, Sigma-Aldrich), ibuprofen sodium salt
(Santa Cruz Biotechnology, Z98%), ibuprofen and ketoprofen
(Sigma, Z98%), MgCl26H2O (VWR, 99%), AlCl36H2O (Acros
Organics, 99%), dichloromethane (DCM; VWR, 99%), acetone
(Fisher Scientific, 99.98%), and sodium hydroxide (Fisher Scientific).
2.2 Synthesis of drug intercalated LDH
Ibuprofen intercalated MgAl–LDH was synthesized using a
hydrothermal method.40,41 A metal precursor solution contain-
ing 2.032 g MgCl26H2O and 1.207 g AlCl39H2O (Mg : Al = 2 : 1)
in 20 mL deionized water was added drop-wise into a second
solution comprising 2.1 g of sodium ibuprofen dissolved in
20 mL of H2O. The pH was kept constant at ca. 9.5 using a
NaOH (1 M) solution, and the subsequent slurry was trans-
ferred into a 100 mL Teflon-lined stainless steel autoclave.
The autoclave was sealed and a hydrothermal reaction per-
formed for 24 h at 100 1C, followed by product recovery through
centrifugation and washing with deionized water until the
supernatant pH was close to 7. A final wash was performed with
acetone in order to produce AMO-LDH particles. Ketoprofen
intercalated LDH was prepared in the same way, except that
the Mg2+/Al3+ solution was added drop-wise into an alkaline
solution containing 2.58 g of ketoprofen in 20 mL H2O.
2.3 Electrospinning
PCL solutions (10% w/v) were prepared by dissolving the
polymer in a mixture of dichloromethane (DCM) and acetone
(weight ratio 3 : 1) under stirring at room temperature. Ibuprofen
and ketoprofen were added at concentrations of 2% and
5% (w/w, based on the dry weight of the polymer). The solutions
were then stirred again until complete dissolution of the drug
had occurred. Working fluids for producing drug–LDH loaded
fibers were prepared by adding the relevant nanocomposite to a
10% w/v PCL solution in 3 : 1 DCM : acetone, at 5 and 10% w/w
with respect to the dry weight of the polymer.
For electrospinning, solutions were loaded into a plastic
syringe fitted with a flat-tipped needle with an inner diameter
of 0.61 mm (Nordson EFD). The solution was ejected at a
speed of 0.8 mL h1, controlled by a syringe pump (KDS100,
Cole-Parmer), with a distance of 15 cm between the tip of the
needle and the collector. A voltage of 16 kV was applied between
the needle and collector using a high-voltage power supply
(HCP35-35000, FuG Elektronik). Fibers were deposited on a flat
piece of steel covered with aluminum foil, forming mats which
could be peeled oﬀ for subsequent experiments.
2.4 Characterization
The morphologies of the LDH particles and fibers were examined
using a scanning electron microscope (SEM; FEI Quanta 200
instrument) with an accelerating voltage of 5.0 kV. The samples
were sputter coated with a thin gold layer before assessment to
prevent charging and to improve image quality. To calculate their
mean size, the diameters of the fibers were measured at more
than 100 points in the SEM images. Energy dispersive X-ray
spectroscopy (EDX) was carried out using a Hitachi S3400N
microscope fitted with an Oxford Instruments EDX detector,
and data analysed using the Inca software.
X-ray diﬀraction (XRD) patterns were recorded on a Rigaku
MiniFlex 600 instrument in reflection mode with Cu Ka radia-
tion (l = 1.5418 Å). The accelerating voltage was set at 40 kV
with 15 mA current. Diﬀraction patterns were obtained over the
range of 2–701 at a scanning rate of 51min1. Fourier transform
IR analyses were carried out on a Spectrum 100 instrument
(PerkinElmer) over the range 650–4000 cm1 at a resolution
of 4 cm1. Differential scanning calorimetry (DSC) analyses
were performed using a Q2000 instrument (TA Instruments).
Approximately 5 mg of each sample was loaded into an aluminum
pan and heated from 0 to 160 1C at a rate of 10 1C min1 under a
nitrogen flow rate of ca. 50 mL min1.
In the case of the LDH particles, the average hydrodynamic
particle size and the size distribution were measured by dynamic
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light scattering (DLS) on a Zetasizer instrument (Malvern
Instruments), after the particles were dispersed in ethanol
via ultrasonication for 30 min. C, H, and N contents were
determined using the combustion method on a Flash 2000
Elemental Analyser (Thermo Scientific).
2.5 In vitro drug release studies
Drug release from the drug–LDH intercalates was performed by
dispersing 10 mg of the particles into 150 mL of phosphate
buffered saline (PBS) at pH = 7.4 and stirring at 37 1C. At
predetermined time points, 3 mL aliquots were taken out and
replaced with fresh pre-heated phosphate buffer to maintain a
constant volume. The samples were filtered through a 0.22 mm
filter, after which the drug concentrations were measured using
a UV-vis spectrophotometer (7315 spectrometer, Jenway) at
222 nm for ibuprofen and 204 nm for ketoprofen.
For the fibers, 200 mg of each fiber mat was placed into 150 mL
of PBS at 37 1C under magnetic stirring. At selected time intervals,
3 mL of the solution was withdrawn for analysis, and 3 mL of fresh
pre-heated phosphate buﬀer added to maintain a constant volume.
Drug concentrations were quantified using UV spectroscopy
following identical procedures to those for the LDH systems.
3. Results and discussion
3.1 Synthesis of LDH–drug nanoparticles
XRD analysis was first used to verify the intercalation of drug
ions into the LDH particles. The XRD patterns are shown in
Fig. 2(a). Both drug–LDH samples have well-developed lamellar
structures, characterized by a series of basal diffractions at low
2y angles and weaker non-basal diffractions at higher angles.
The interlayer spacing (d003) values of Mg/Al LDH interca-
lated with inorganic anions (e.g. nitrate) is reported to be
B0.88 nm.42 The distance between adjacent layers is larger
with ibuprofen or ketoprofen anions in the interlayer space, at
2.19 and 2.15 nm respectively. This demonstrates that the drug
ions were intercalated into the LDH particles, and these values
are in good agreement with previous reports.27,43 The expanded
interlayer separation is due to the molecular size and geo-
metrical arrangement of the anions in the interlayer space.44
As the layer thickness of an LDH is 0.48 nm,45 the gallery
heights (defined as the interlayer spacing – the layer thickness)
of the ibu–LDH and ket–LDH hybrids are ca. 1.71 and 1.67 nm,
respectively. This suggests that the ibu and ket ions are arranged
as a slightly tilted bilayer with their long axes perpendicular to
the metal hydroxide layer.46 Such an arrangement permits the
carboxylate groups to interact with the layer surfaces.
IR spectra are given in Fig. 2(b and c). Fig. 2(b) depicts
the FT-IR spectra of ibuprofen and the ibu–LDH nanohybrid.
The characteristic bands at 2962, 2919, and 2867 cm1 for pure
ibuprofen are attributed to the alkyl stretching vibrations. The
peaks at 1547 and 1402 cm1 are due to asymmetric and sym-
metric RCOOH stretches, respectively. These have been observed
at around 1550 and 1400 cm1 in previous studies,27,47,48 and
shift to 1541 and 1399 cm1 in the ibu–LDH nanohybrids. This
is expected to arise as a result of hydrogen bonding and
electrostatic interactions between the RCOO groups and the
LDH layers in the intercalate.46 The weak bands at 1511 and
1466 cm1 in the ibuprofen and ibu–LDH spectra are assigned
to aromatic ring vibrations.
Pure ketoprofen (Fig. 2(c)) shows characteristic absorption
peaks at 3054 and 2979–2878 cm1, denoting stretching vibra-
tions of aromatic and methyl C–H groups. The bands at 1697
and 1654 cm1 are due to CQO stretching of the carboxylic acid
and ketone groups respectively.49 Peaks at 1596 and 1443 cm1
Fig. 2 (a) XRD patterns of ibuprofen and ketoprofen intercalated LDH,
with FT-IR spectra of (b) pure ibuprofen and ibu–LDH, and (c) pure
ketoprofen and ket–LDH.
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can be attributed to CQC stretching of the aromatic ring. As
was observed for ibuprofen, the carboxylate stretches shift in
position after intercalation, indicating the formation of inter-
actions between the LDH layer and the guest anions.
The IR spectra of both ibu–LDH and ket–LDH also show a
very broad band centered at approximately 3400 cm1, which
corresponds to v(OH) stretching vibrations of the hydroxyl
groups of the host layers. The observations from IR spectro-
scopy thus concur with the XRD data, demonstrating successful
intercalation of ibu and ket into the LDH gallery. Elemental
analysis measurements (Table S1, ESI†) reveal that the average
loading of ibuprofen and ketoprofen in the intercalates was
42.01  2.55% and 45.89  0.76% w/w, respectively.
The morphologies of the LDH particles were characterized
using SEM analysis (Fig. 3). Both ibu–LDH and ket–LDH exist as
aggregated plate-like nanoparticles. The lateral diameters of
the particles are 147  37 nm and 179  35 nm, respectively.
The hydrodynamic diameters measured by dynamic light
scattering (DLS) are rather larger than those determined from
the SEM images, with DLS giving sizes of 296  3 nm and
315  13 nm for the ibu– and ket–LDH systems respectively.
This is consistent with previous work, for instance that reported
by Xu et al.50 The larger particle size from DLS can partially
be attributed to the particles being hydrated, but the large
difference between the SEM and DLS results also suggests that
the LDH–drug nanoparticles were not completely dispersed in
the DLS experiment, and some aggregates were present.
3.2 Electrospun fibers
XRD patterns, given in Fig. 4, provide information on the
physical form of the drug and drug–LDH nanohybrids in the
polymer matrix. Pure PCL has a semi-crystalline structure with
two main reflections at 21.31 and 23.61. When fibers were
prepared with 2 and 5% w/w ibu (Fig. 4(a)), only the typical
peaks of PCL can be seen in the patterns. This shows that
the drug is amorphously dispersed in the polymer matrix
after electrospinning, most likely as a solid solution, and is
consistent with numerous previous reports of drug loaded
electrospun fibers.11 For the PCL/ibu–LDH fibers, a reflection
at 2y = 41 is visible in Fig. 4(a), together with a weak peak at 81.
These correspond to the (003) and (006) reflections of ibu–LDH,
indicating that the dispersed LDH retains an ordered structure
after electrospinning. They are also more intense with the
10% w/w loading than with 5%, as would be intuitively expected.
The overall drug loading in the fibers is calculated to be 4.20% w/w
for the PCL/10% ibu–LDH fibers, and 2.10% for the PCL/5%
ibu–LDH analogue.
The results with the ketoprofen systems are analogous to
those with ibuprofen. The characteristic reflections of ketopro-
fen were completely absent in the PCL/ket nanofibers (Fig. 4(b)),
even at 5% w/w loading, again confirming an amorphous drug
distribution. Typical reflections of the ket–LDH hybrid can be
seen in the PCL/ket–LDH fibers (Fig. 4(b)), with these being more
distinctive at higher loading. The final drug loadings are 4.59
and 2.29% w/w for the PCL/10% ket–LDH and PCL/5% ket–LDH
materials respectively.
SEM micrographs of the electrospun PCL–drug and PCL/
LDH–drug composites are shown in Fig. 5. All the drug-loaded
and LDH/drug-loaded fibers are largely smooth and cylindrical
in morphology, but the LDH-free fibers show evidence of
solvent inclusion in the form of merged fibers. The average
diameter of the fibers ranges from 400 nm to 1000 nm. There is
Fig. 3 SEM images of (a) ibu–LDH and (b) ket–LDH, with particle size distributions.
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some influence of the drug or LDH–drug loading on the fiber
diameters: in most (but not all) cases, the diameter increases with
increasing drug or LDH–drug loading. The ketoprofen systems have
consistently larger and more homogeneous diameters than their
ibuprofen analogues. In general, the LDH-containing fibers have
more homogeneous fiber diameters than the analogous LDH-free
materials. The reasons for these variations are not entirely clear: the
mechanism of electrospinning is extremely complicated, and many
factors influence the fiber diameters due to a complex interplay
between fluid dynamics, electrodynamics, and rheology.51,52
The drug–LDH distribution in the PCL composites was
explored using SEM-EDX analyses. Elemental mapping results
for Mg and Al are given in Fig. 6. Mg and Al are distributed evenly
throughout the fibers, indicating that the drug loaded LDH
nanoparticles were well dispersed as a result of the AMOST
process. This renders the surfaces of the LDH particles somewhat
hydrophobic, and thus they can efficiently mix with the PCL
carrier matrix, rather than aggregating on the surface. In addition,
the EDX also showed that the ratio of Mg/Al is around 2.
DSC analyses were performed to evaluate the crystallinity of
the fiber systems, and the results are depicted in Fig. 7. The
endothermic peak for pure PCL at 63.4 1C corresponds to its
melting point, which is reported to lie the range from 59 to
64 1C.53,54 The DSC curves of ibuprofen and ketoprofen showed
sharp endothermic peaks at 77.4 1C and 94.3 1C respectively,
corresponding to their melting points and confirming the two
raw materials to be crystalline. These values agree well with the
literature.46,49,55,56 The DSC curves of physical mixtures of PCL
and either drug show two endothermic peaks, corresponding to
the melting points of the two components in the mixture. For
the PCL + ibu physical mixture, the endothermic peaks are at
60.8 and 77.0 1C (Fig. 7(a)), whereas the PCL + ket mixture
showed melts at 61.5 and 95.7 1C (Fig. 7(b)). Thus, as would be
expected, simply making a physical mixture does not change
the physical form.
In contrast, the DSC curves of the PCL based nanofibers
showed only a single peak in the temperature range from 53 to
61 1C, which arises due to melting of the PCL. The peak is
slightly shifted to lower temperatures compared to pure PCL,
suggesting a reduction in the polymer’s crystallinity and the size
of its crystals. The degree of crystallinity (Xc) can be calculated
from the melting peak areas using the following equation:57
Xc ¼ DHmDHm f
Fig. 4 XRD patterns of the various (a) ibuprofen and (b) ketoprofen
containing nanocomposites.
Fig. 5 SEM images of (a) PCL/2% ibu, (b) PCL/2% ket, (c) PCL/5% ibu,
(d) PCL/5% ket, (e) PCL/5% ibu–LDH, (f) PCL/5% ket–LDH, (g) PCL/10%
ibu–LDH, and (h) PCL/10% ket–LDH fibers, with the corresponding
diameter distributions.
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where DH

m is the heat of fusion for a theoretically 100%
crystalline PCL sample (taken to be 146 J g1),2 DHm is the
melting enthalpy of the sample of interest, and f is the weight
fraction of polymer in the system. The results of these calcula-
tions are listed in Table 1. After incorporation of the drugs or
LDH–drug nanohybrids in the PCL matrix, both DHm and Xc
decreased, indicating that there are some interactions between
PCL and the drug or drug–LDH particles.
Fig. 6 SEM images, Mg, and Al elemental mapping of the PCL/drug–LDH
fibers. (a) PCL/5% ibu–LDH, (b) PCL/5% ket–LDH, (c) PCL/10% ibu–LDH,
and (d) PCL/10% ket–LDH.
Fig. 7 DSC curves (exo up) of the (a) ibuprofen and (b) ketoprofen based
nanocomposites. PCL + ibu and PCL + ket denote physical mixtures of the
drug and polymer with a mass ratio 5 : 1.
Table 1 Calorimetric data for the various PCL composites
Samples Tm (1C) DHm (J g
1) Xc (%)
PCL 63.43 79.35 54.35
PCL/2% ibu 56.91 68.17 47.64
PCL/5% ibu 56.84 56.37 40.64
PCL/5% ibu–LDH 55.19 47.99 34.60
PCL/10% ibu–LDH 54.82 47.61 36.23
PCL/2% ket 53.08 54.00 37.74
PCL/5% ket 53.71 52.86 38.11
PCL/5% ket–LDH 54.41 48.49 34.96
PCL/10% ket–LDH 53.82 46.92 35.71
Fig. 8 Drug release profiles of (a) the drug–LDH nanoparticles, (b) PCL/
ibu fibers, and (c) PCL/ket fibers. The data points represent the mean S.D.
of three independent experiments.
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The melting endotherms of ibuprofen and ketoprofen were
both absent from the PCL/drug fibers. This concurs with the
XRD data and confirms the PCL/ket and PLC/ibu fibers to be
amorphous solid dispersions. Considering the PCL/LDH–drug
fibers, again no endotherms are visible other than the melt of
PCL. This is because the drug ions in the LDH interlayer spaces
do not adopt the same arrangement as in the pure drug
crystals, and the major degradation events of the LDH lie above
the upper temperature of the DSC experiment.
3.3 In vitro drug release
Fig. 8 shows the cumulative drug release profiles from the drug
loaded LDH nanoparticles and the PCL/drug fibers in PBS (pH = 7.4)
at 37 1C. Significant bursts of release (480% in the first 2 h) were
seen with both the LDH–drug materials (Fig. 8(a)). Ibu–LDH initially
releases more slowly but eventually reaches a higher release percen-
tage than ket–LDH. This can perhaps be explained by the fact
that ibuprofen is a smaller ion with greater charge density than
ketoprofen, and thus should have stronger interactions with the
LDH layers. This will lead to a higher energy barrier to release,
causing ibuprofen to releasemore slowly. At the same time, however,
ibuprofen is more water soluble than ketoprofen, and so eventually
it is thermodynamically favorable for a larger percentage to release.
No further release is observed after 4 h for both LDH–drug systems.
Both drugs are released more slowly from the PCL/drug
fibers than from the LDH interlayers (Fig. 8(b) and (c)). Over
60% of the incorporated drug is released within the first 4 h in
all cases. With the PCL/ibu systems, an increase in the drug
loading causes an acceleration in the release rate and extent:
the PCL/5% ibu fibers free almost 85% of their drug content in
4 h. This can be explained because the higher loading will lead
to more pores being formed in the fibers as drug molecules
escape into solution, making it easier for ibuprofen molecules
near the center of the fibers to diﬀuse to the release milieu. In
contrast, the two ketoprofen loadings show essentially identical
release profiles. This is likely to be a result of both stronger
drug–polymer intermolecular interactions in the case of keto-
profen (PCL is hydrophobic, and ketoprofen more hydrophobic
than ibuprofen), and its lower solubility.
The drug release profiles from the PCL/LDH–drug compo-
sites are included in Fig. 9. Fig. 9(a) and (b) give the drug
release profile over 120 h, while Fig. 9(c) and (d) contain an
enlargement of the first 24 h. The PCL/LDH–drug composites
are able to reduce the initial burst of release profoundly
(Table 2). The materials present a fast release in the initial
period of the experiment, followed by a very slow release. The
first stage is due to the presence of some LDH–drug particles at
or close to the surface of fibers. Drug release from these
depends on the ion exchange reaction time, which is very rapid
and is completed in about 2 h.2 During this period, approxi-
mately 13 and 26% of the incorporated ibuprofen (or 13 and
10% of ketoprofen) are released from the systems with 5 and
10% LDH–drug loadings, respectively.
The second and third stages of release start after two hours,
and are due to the drug escaping from the inside of the polymer
matrix. Here, the release time depends on a number of factors:
Fig. 9 Drug release profiles for (a) PCL/ibu–LDH over 5 days, (b) PCL/ket–LDH over 5 days, with enlargements of the first 24 h for (c) PCL/ibu–LDH, and
(d) PCL/ket–LDH. The data points represent the mean  S.D. of three independent experiments.
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the diﬀusion behavior of the replacement phosphate ions entering
the polymer/LDH matrix, the ion-exchange reaction time, and the
diﬀusion of the drug ions escaping the fiber. This process is very
slow and release extending for several days is observed.2 The fibers
give an almost constant rate of release between 24–120 h, and
fitting zero-order kinetics to the data over this period gives R2 values
40.9 (see Fig. S1, ESI†). After 5 days, approximately 44 and 48% of
the ibuprofen loading is released for the 5 and 10% w/w fibers,
while for ketoprofen the equivalent values are 25 and 20%.
The Ritger–Peppas and Bhaskar equations were also applied




where Mt/MN represents the fraction of drug released at time t,
k is a rate constant and the exponent n gives information on the
underlying release mechanisms. The parameters k and n can be
calculated by plotting log(Mt/MN) against log(t).
43,58
The Bhaskar model assumes that diﬀusion through the
particle is the rate limiting step to release, making it appro-
priate for ion-exchange processes. It takes the form:59
1 Mt
M1
¼ exp 16:33 k
l2
 0:65" #
where Mt/MN represents the fraction of drug released at
time t, k is the rate constant and l is the particle size in the
ab-direction, calculated from the d110 reflection.
Fig. S2 (ESI†) depicts the fits obtained with both the Ritger–
Peppas and Bhaskar equations: while the fits with the former
are generally good with R2 4 0.96, the latter are clearly non-
linear, with R2 typically below 0.9. The Peppas exponents are
mostly below 0.45, which for a cylindrical dosage form such as a
fiber is consistent with release governed by Fickian diffusion. The
complexity of the system makes it difficult to be certain of the
drug release mechanism, but the fact that the Peppas model gives
good fits while the Bhaskar equation does not might indicate that
the diffusion of drug through the PCL fibers is the rate limiting
step to release (rather than ion-exchange in the LDH particles).
The use of the AMOST approach leads to significant
improvements over previous work in this area: in the previous
work by Miao et al.,11 it was found that the PCL/LDH nanofibers
could slow the release of ibuprofen, but very rapid release was
still observed in the first 1–2 h, and a plateau reached after 2 h.
In contrast, our systems give a constant and sustained rate of
release over at least 5 days, giving them great potential as
implantable drug delivery systems.
4. Conclusions
Sustained drug release materials based on PCL fibers containing
drug-intercalated LDH nanoparticles have been prepared and
fully characterized. The fibers are found to be smooth and
cylindrical, with the LDH-containing systems having more homo-
genous fibers than those without the inorganic filler. These
systems are able to profoundly extend the drug release period
over both PCL/drug fibers and LDH–drug particles alone. The use
of ternary PCL/LDH–drug formulations also reduces the initial
burst of release seen with the binary systems. More than 80% of
the ibuprofen and ketoprofen loadings were released from the
LDH–drug particles within 2 h, while release from the PCL/drug
fibers reached at least 60% after 4 h and plateaus after 10 h. In
contrast, the PCL/LDH–drug materials free only 10–26% of their
drug loading after 2 h and extend release over more than 5 days.
The PCL/ibu–LDH materials in particular give an almost constant
rate of release from 10–120 h, and thus may have great potential
in developing implantable drug delivery systems.
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